Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
Author:
Affiliation:
1. TP Therapeutics, Inc., 6150 Lusk Boulevard, Suite B100, San Diego, California 92121, United States
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/jm401427c
Reference184 articles.
1. The Protein Kinase Complement of the Human Genome
2. Cell Signaling by Receptor Tyrosine Kinases
3. The discovery of receptor tyrosine kinases: targets for cancer therapy
4. MET signalling: principles and functions in development, organ regeneration and cancer
5. Targeting MET in cancer: rationale and progress
Cited by 181 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Discovery of LAH-1 as potent c-Met inhibitor for the treatment of non-small cell lung cancer;Journal of Enzyme Inhibition and Medicinal Chemistry;2023-12-11
2. Exploring marine-derived compounds for MET signalling pathway inhibition in cancer: integrating virtual screening, ADME profiling and molecular dynamics investigations;SAR and QSAR in Environmental Research;2023-11-28
3. Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding;Journal of Biological Chemistry;2023-11
4. Synthesis and preclinical evaluation of a selective MET kinase positron emission tomography tracer;Journal of Labelled Compounds and Radiopharmaceuticals;2023-10-22
5. MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target;Cancers;2023-09-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3